drugset / Trial / NCT00508326
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
Timeline
- Start
- 2005-10
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | Other |
Indications
No indication recorded.